We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+14.19%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$689M
AUM Growth
-$53.2M
Cap. Flow
-$90.8M
Cap. Flow %
-13.19%
Top 10 Hldgs %
41.31%
Holding
80
New
3
Increased
6
Reduced
50
Closed
5

Top Buys

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$20.9M
2
JUNO
Juno Therapeutics, Inc.
JUNO
+$13.9M
3
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$9.22M
4
FWP
Forward Pharma A/S American Depositary Shares
FWP
+$6.73M
5
CHRS icon
Coherus Oncology
CHRS
+$2.49M

Top Sells

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$22.7M
2
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$15.6M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$10.7M
4
HRTX icon
Heron Therapeutics
HRTX
+$10.4M
5
BPMC
Blueprint Medicines
BPMC
+$8.66M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Miscellaneous 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AAAP
51
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$2.99M 0.43%
75,000
-49,220
-40% -$1.7M
LPCN icon
52
Lipocine
LPCN
$18.2M
$2.89M 0.42%
43,617
-577
-1% -$37.4K
ASND icon
53
Ascendis Pharma A/S
ASND
$16.3B
$2.8M 0.41%
100,000
-62,254
-38% -$1.57M
OTLK icon
54
Outlook Therapeutics
OTLK
$167M
$2.69M 0.39%
6,266
+1,058
+20% +$526K
EPZM
55
DELISTED
Epizyme, Inc
EPZM
$2.4M 0.35%
140,000
-19,513
-12% -$260K
RGNX icon
56
Regenxbio
RGNX
$520M
$2.32M 0.34%
120,000
-36,741
-23% -$709K
IMDZ
57
DELISTED
Immune Design Corp.
IMDZ
$2.29M 0.33%
337,000
-95,990
-22% -$555K
AVXS
58
DELISTED
AveXis, Inc. Common Stock
AVXS
$2.28M 0.33%
30,000
-19,991
-40% -$1.24M
VIRX
59
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.13M 0.31%
14,862
-13,709
-48% -$1.96M
TIG
60
DELISTED
TiGenix American Depositary Shares
TIG
$2.01M 0.29%
129,032
– –
ABEO icon
61
Abeona Therapeutics
ABEO
$304M
$2M 0.29%
16,000
-4,000
-20% -$516K
XLRN
62
DELISTED
Acceleron Pharma
XLRN
$1.99M 0.29%
75,000
-52,451
-41% -$1.38M
XNCR icon
63
Xencor
XNCR
$1.79B
$1.79M 0.26%
75,000
-25,000
-25% -$602K
CRVS icon
64
Corvus Pharmaceuticals
CRVS
$1.05B
$1.68M 0.24%
81,000
-117,526
-59% -$1.84M
CBIO
65
Crescent Biopharma
CBIO
$657M
$1.56M 0.23%
2,870
– –
HTGM
66
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$1.41M 0.2%
1,130
– –
MYOV
67
DELISTED
Myovant Sciences Ltd.
MYOV
$1.17M 0.17%
100,000
– –
APTO
68
DELISTED
Aptose Biosciences, Inc.
APTO
$1.01M 0.15%
2,201
– –
MTEM
69
DELISTED
Molecular Templates, Inc.
MTEM
$513K 0.07%
5,455
-680
-11% -$63.6K
AVEO
70
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$413K 0.06%
70,000
-38,772
-36% -$280K
NEOS
71
DELISTED
Neos Therapeutics, Inc
NEOS
$364K 0.05%
50,613
– –
ONSIW
72
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$333K 0.05%
416,666
– –
ONSIZ
73
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$208K 0.03%
416,666
– –
CLRB icon
74
Cellectar Biosciences
CLRB
$22.3M
$122K 0.02%
18
– –
CLRBW
75
DELISTED
Cellectar Biosciences, Inc.
CLRBW
$20K ﹤0.01%
52,999
– –
1 2
3
4

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q1 2017 Portfolio in Review

As of Q1 2017, Cormorant Asset Management held 80 positions worth $689M, down 7.2% from $742M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Cormorant Asset Management withdrew a net $90.8M in Q1 2017, closing 5 positions and reducing 50 holdings. Its most notable exit was Concert Pharmaceuticals, Inc., an estimated $5.54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Cormorant Asset Management opened a new position in AnaptysBio worth $24.9M.

  • Cormorant Asset Management's largest Q1 2017 buy was AnaptysBio: 895,626 shares worth $24.9M.
  • Cormorant Asset Management added most to Forward Pharma A/S American Depositary Shares in Q1 2017, an estimated $6.73M increase.
  • Cormorant Asset Management's biggest Q1 2017 reduction was NEVRO CORP., cutting an estimated $22.7M.
  • Cormorant Asset Management fully exited Concert Pharmaceuticals, Inc. in Q1 2017, selling an estimated $5.54M.
  • Cormorant Asset Management's ten largest holdings make up 41% of its $689M portfolio in Q1 2017.
  • Cormorant Asset Management opened 3 new positions and closed 5 in Q1 2017.
  • Cormorant Asset Management's portfolio value fell 7.2% quarter-over-quarter to $689M.

Based on Cormorant Asset Management's 13F filing for Q1 2017, filed 15 May 2017.